Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.
Puyalto A, Rodríguez-Remírez M, López I, Iribarren F, Simón JA, Ecay M, Collantes M, Vilalta-Lacarra A, Francisco-Cruz A, Solórzano JL, Sandiego S, Peñuelas I, Calvo A, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: calvo a. Front Immunol. 2023 Sep 28;14:1272570. doi: 10.3389/fimmu.2023.1272570. eCollection 2023. Front Immunol. 2023. PMID: 37841258 Free PMC article.
Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C, Varela CF, Ummarino A, Maeda A, Sironi M, Gandoy S, Brea J, Loza MI, León S, Calvo A, Correa J, Fernandez-Megia E, Alonso MJ, Allavena P, Crecente-Campo J, Andón FT. Anfray C, et al. Among authors: calvo a. Front Immunol. 2024 Jan 8;14:1334800. doi: 10.3389/fimmu.2023.1334800. eCollection 2023. Front Immunol. 2024. PMID: 38259462 Free PMC article.
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: calvo a. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S, Öztürk SC, Yanik H, Tavukcuoglu E, Şahin A, Datta D, Charisse K, Álvarez DM, Loza MI, Calvo A, Sulheim E, Loevenich S, Klinkenberg G, Schmid R, Manoharan M, Esendağlı G, Alonso MJ. Anthiya S, et al. Among authors: calvo a. J Control Release. 2023 May;357:67-83. doi: 10.1016/j.jconrel.2023.03.016. Epub 2023 Mar 28. J Control Release. 2023. PMID: 36921725 Free article.
Emotion Processing in Peripheral Neuropathic Pain: An Observational Study.
Isoardo G, Adenzato M, Ciullo S, Fontana E, Stura I, Migliaretti G, Titolo P, Matteoni E, Calvo A, Laino F, Palumbo F, Ardito RB. Isoardo G, et al. Among authors: calvo a. Med Sci (Basel). 2024 May 17;12(2):27. doi: 10.3390/medsci12020027. Med Sci (Basel). 2024. PMID: 38804383 Free PMC article.
Update on recent advances in amyotrophic lateral sclerosis.
Riva N, Domi T, Pozzi L, Lunetta C, Schito P, Spinelli EG, Cabras S, Matteoni E, Consonni M, Bella ED, Agosta F, Filippi M, Calvo A, Quattrini A. Riva N, et al. Among authors: calvo a. J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12435-9. Online ahead of print. J Neurol. 2024. PMID: 38802624
Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study.
Chamorro-de-Vega E, Calvo A, Fernández-Pacheco M, Hernández-Muniesa B, Romero-Jiménez R, Casado-Gómez A, Ramírez E; Grupo de Trabajo Estudio SACVINFA:; Morell A, Herrero N, Úbeda B, Ais-Larisgoitia A, Lobato-Matilla E, Muñoz Á, Casado MÁ, Escudero-Vilaplana V. Chamorro-de-Vega E, et al. Among authors: calvo a. Farm Hosp. 2024 May 23:S1130-6343(24)00056-4. doi: 10.1016/j.farma.2024.04.006. Online ahead of print. Farm Hosp. 2024. PMID: 38789316 Free article. English, Spanish.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Lancet Neurol. 2024 May 20:S1474-4422(24)00134-0. doi: 10.1016/S1474-4422(24)00134-0. Online ahead of print. Lancet Neurol. 2024. PMID: 38782015
Use of the combination of spirometry, arterial blood gas analysis and overnight oximetry to predict the outcomes of patients affected by motor neuron disease: The Milan-Torin respiratory score (Mi-To-RS).
Schito P, Manera U, Russo T, Cremona G, Riboldi E, Tettamanti A, Agosta F, Quattrini A, Chiò A, Filippi M, Calvo A, Riva N. Schito P, et al. Among authors: calvo a. Eur J Neurol. 2024 May 8:e16316. doi: 10.1111/ene.16316. Online ahead of print. Eur J Neurol. 2024. PMID: 38716751
1,095 results